Gilead taps Korea's Yuhan to supply HIV drug ingredients in …
WEB9 hours ago · In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s Yuhan to help produce its HIV meds in a deal worth $80.9 million.
Yuhan inks $80.9 million deal with Gilead Sciences for HIV ... - MSN
WEBYuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drug maker ...
Yuhan terminates cancer drug deal with J&J, signs new API …
WEB22 hours ago · The deal, valued at approximately $80.9 million (107.6 billion won), is equivalent to 5.79 percent of Yuhan's 2023 annual sales. This agreement is set to run from Friday to September 30, 2025. Yuhan has been collaborating with Gilead Sciences in the field of hepatitis B and C treatments since 2003. tweet
Yuhan inks $81 mn contract with U.S. Gilead to supply HIV …
WEB1 day ago · South Korean pharmaceutical company Yuhan Corp. announced on Friday that it has signed a contract with U.S. biopharmaceutical company Gilead Sciences Inc. to supply raw materials for human immunodeficiency virus (HIV) treatments. The contract is worth 107.6 billion won ($80.8 million), which is 5.79 percent of Yuhan’s sales in 2023.
Yuhan, Janssen halt next-gen cancer drug collaboration - The …
WEB16 hours ago · Yuhan's corporate logo (Yuhan) South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted ...
유한양행, 길리어드와 1000억 원대 HIV 치료제 원료의약품 공급계약
WEB19 hours ago · 유한양행은 글로벌 제약사 길리어드 사이언스 (길리어드)와 인체면역결핍바이러스 (HIV) 치료제 원료의약품 (API) 공급 계약을 체결했다고 20일 ...
Gilead Sciences and Yuhan Corporation Announce Collaboration …
WEBJan 6, 2019 · Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development. Gilead will also be responsible for commercialization worldwide, outside of Yuhan’s rights in the Republic of Korea.
Gilead adds another shot on the NASH goal with $785M Yuhan pact
WEBJan 7, 2019 · It now adds a new program from South Korean biotech Yuhan to its pipeline, although exact details are thin on the ground.
Gilead Sciences and Yuhan Corporation Announce Collaboration …
WEBJan 6, 2019 · Gilead Sciences Inc. and Yuhan Corporation announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of...
Gilead Inks $785 Million Deal With Yuhan for NASH Development
WEBJan 7, 2019 · Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).
- Some results have been removed
Skip to content